Details of the SBP

General Information of Synthetic Binding Protein (SBP) (ID: SBP000159)
SBP Name
DART MGD-019
Synonyms
MGD019
Design Method Traditional methods (Site-directed mutagenesis and/or Directed evolution)
Highest Status Phase I
Protein Scaffold Information of This SBP
Scaffold ID PS028
Scaffold Info
[1]
Scaffold Name DART
Scaffold Class Antibody fragment
Fold Type Beta-Sheets + Loops
Binding Target(s) of This SBP (BTS)
BTS Name Details Mechanism Application Affinity Research Organization Ref
Programmed cell death protein 1
BTS Info
Inhibitor Solid tumour/cancer [ICD-11: 2A00-2F9Z] N.A. MacroGenics [1]
Cytotoxic T-lymphocyte protein 4
BTS Info
Inhibitor Solid tumour/cancer [ICD-11: 2A00-2F9Z] N.A. MacroGenics [1]
Clinical Trial Information of This SBP
NCT03761017 Click to show the Detail
Indication Unresectable or Metastatic Neoplasms
Phase Phase I
Title A Phase I, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of?MGD019, a Bispecific DART? Protein Binding PD-1 and CTLA-4 in Patients With Unresectable or Metastatic Neoplasms
Status Recruiting
Sponsor MacroGenics
NCT05293496 Click to show the Detail
Indication Advanced Solid Tumor; Castration-Resistant Prostatic Cancer; Malignant Melanoma; Pancreatic Ductal Carcinoma; Hepatocellular Cancer; Epithelial Ovarian Cancer; Renal Cell Carcinoma
Phase Phase I
Title A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
Status Recruiting
Sponsor MacroGenics
NCT05475171 Click to show the Detail
Indication Metastatic Cancer; Cervical Cancer
Phase Phase II
Title Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
Status Recruiting
Sponsor M.D. Anderson Cancer Center
NCT05848011 Click to show the Detail
Indication Androgen-Independent Prostatic Cancer; Androgen-Independent Prostatic Neoplasms; Prostate Cancer Recurrent; Androgen-Insensitive Prostatic Cance; Androgen-Resistant Prostatic Cancer; Hormone Refractory Prostatic Cancer; Immunotherapy; Immune Checkpoint Inhibitor; Inhibitory Checkpoint Molecule
Phase Phase II
Title A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
Status Recruiting
Sponsor MacroGenics
References
1 MacroGenics. Product Development Pipeline. 2021.